Effect of Ranibizumab on Malignant Conjunctival Neoplasia

Completed · Phase 1

Conditions studied: Conjunctival Neoplasms

In brief

The purpose of this study is to test the safety and tolerability of subconjunctival injection of ranibizumab in the treatment of malignant conjunctival neoplasia using the incidence and severity of adverse events. Our secondary objective is to assess the efficacy of ranibizumab treatment on malignant conjunctival neoplasia by evaluating tumor destruction or reduction as documented by slit-lamp photography and ultrasonographic imaging and the regression of blood vessels.

Key facts

Study ID
NCT00456495
Run by
The New York Eye Cancer Center
People needed
5
Starts
2007-03-01
Expected to finish
2010-09-01
Last updated by the study team
2017-07-21

Who can join

Age: 21 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.